/ Suven Life Sciences Secures Patents In Australia, USA ~ Ways2Capital|Stock Tips|Stock Market Tips|Intraday Stock Tips|Stock Trading Tips|NSE BSE Tips

Tuesday, 13 June 2017


Suven Life Sciences on Tuesday announced the grant of one product patent from Australia and one product patent from USA corresponding to the New Chemical Entities (NCEs).

The product is used for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2032 and 2034, respectively.

The granted claims of the patents are from the mechanism of action include the class of selective 5HT6 and 5HT4 compounds and are being developed as therapeutic agents.

These compounds are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and schizophrenia.

In addition to these clinical compounds, the company has nine internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and pain.

or Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.com
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔ 
Give a Missed Call for Free Trial - 09699997717 ✔

0 comments: